GCM Grosvenor

GCMG · NASDAQ

$12.58+$0.24 (+1.94%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $12.34

GCMG analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy3
Hold1
Underperform0
Sell0

12-month price target · 6 analysts

Average $16.66 (+32.4% upside)

Low: $16.16
Now: $12.58
High: $17.85

Upgrades and downgrades

The latest rating actions, newest first

GCMG analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Oct 19, 2026	Maintains	Overweight	$16.00 → $14.50	37%
JP Morgan	Aug 11, 2026	Maintains	Neutral	$12.00 → $13.00	53%
Piper Sandler	Aug 11, 2026	Maintains	Overweight	$15.00 → $16.00	37%
Oppenheimer	Jul 17, 2026	Maintains	Outperform	$18.00 → $17.00	67%
Piper Sandler	Jul 13, 2026	Maintains	Overweight	$13.00 → $15.00	37%
TD Cowen	May 26, 2026	Maintains	Buy	$13.50 → $14.00	53%
Oppenheimer	May 11, 2026	Maintains	Outperform	$17.00 → $18.00	67%
Oppenheimer	Apr 13, 2026	Maintains	Outperform	$24.00 → $17.00	67%
Piper Sandler	Apr 7, 2026	Maintains	Overweight	$14.50 → $13.00	37%

The case for and against

Updated Oct 15, 2026

Bull case

GCM Grosvenor is attractive because it is delivering solid operating momentum, with 2Q26 fundraising of $2.3B up from $1.5B in 1Q26, adjusted EPS of $0.19 above expectations, and FRE margin of 45%, showing healthy fee generation and expense discipline. Its outlook is further strengthened by management’s confidence in 2H26 fundraising exceeding 1H26, an ARS pipeline described as the strongest in at least 10 years, and recurring wealth-channel and private markets growth supported by scaling AUM and operating leverage. The stock also has meaningful hidden upside from more than $1B of unrealized carried interest, a $150M SpaceX stake valued at about $3.5B, and long-term targets of over $280M in FRE and more than $1.20 in adjusted net income per share by 2028.

Bear case

GCM Grosvenor is facing a cautious setup because management’s assumption of wealth contribution appears limited, and the robust $500M in gross sales in 1Q26 may prove difficult to sustain at the same pace through ’28E. The stock’s fundamentals are pressured by multiple macro risks, including capital market declines, higher or lower interest rates, widening credit spreads, delayed LP allocations, and a shifting competitive landscape, all of which can slow asset gathering, deployment, and monetization. Downside also stems from the possibility of slower than modeled Private Markets organic growth, weaker specialized/custom NNA growth, fee degradation in Private Markets, and a steeper-than-expected AOLR in Absolute Return Strategies.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.